J84.83 Surfactant mutations of the lung

Name of the Condition

• Surfactant mutations of the lung

Summary

Surfactant mutations of the lung are genetic disorders affecting the production or function of pulmonary surfactant, a substance critical for reducing surface tension in the alveoli and maintaining lung stability. These mutations can lead to impaired gas exchange, respiratory distress, and progressive lung damage. The condition is part of a broader group of surfactant dysfunction syndromes, which may present in infancy or later life depending on the specific genetic defect.

Causes

Surfactant mutations result from genetic alterations in genes encoding surfactant proteins (e.g., SFTPB, SFTPC) or components of the surfactant lipid metabolism pathway. These mutations disrupt normal surfactant production, processing, or function, leading to alveolar instability and respiratory compromise. Inheritance patterns may be autosomal dominant or recessive, depending on the specific gene involved.

Risk Factors

• Family history of surfactant-related lung disease.
• Consanguinity (increased risk of recessive mutations).
• Certain ethnic populations with higher carrier frequencies for specific mutations.

Symptoms

• Respiratory distress (e.g., tachypnea, grunting) in infants.
• Recurrent or persistent pneumonia.
• Failure to thrive in pediatric cases.
• Progressive dyspnea and exercise intolerance in older individuals.
• Cyanosis or hypoxemia in severe cases.

Diagnosis

Diagnosis involves a combination of clinical evaluation, genetic testing for surfactant-related genes, and pulmonary function tests. Imaging (e.g., chest X-ray or CT) may show diffuse opacities or ground-glass changes. Lung biopsy with histopathological analysis and surfactant protein assays can confirm the diagnosis. Family screening may be recommended for genetic counseling.

Treatment Options

Treatment focuses on supportive care, including oxygen therapy, mechanical ventilation, and management of respiratory infections. Specific therapies may include surfactant replacement, though outcomes vary by mutation type. Lung transplantation is considered in advanced cases with irreversible respiratory failure.

Prognosis and Follow-Up

Prognosis depends on the severity of the mutation and age of onset. Early-onset forms often have a poor prognosis without intervention, while milder mutations may allow for longer survival with chronic management. Regular follow-up with pulmonology and genetics is essential to monitor lung function and adjust therapies.

Complications

• Chronic respiratory failure.
• Pulmonary hypertension.
• Recurrent respiratory infections.
• Growth failure in pediatric patients.
• Need for long-term oxygen or ventilatory support.

Lifestyle & Prevention

• Avoid exposure to respiratory irritants (e.g., smoke, pollutants).
• Vaccinations to prevent infections (e.g., influenza, pneumococcal).
• Prompt treatment of respiratory illnesses to prevent exacerbations.
• Genetic counseling for families with known mutations.

When to Seek Professional Help

Seek immediate medical attention for sudden worsening of breathing, cyanosis, or respiratory distress. Routine follow-up is recommended for monitoring lung function and managing chronic symptoms.

Tips for Medical Coders

Document the specific genetic mutation (if known) and clinical manifestations to support coding. Ensure documentation aligns with the ICD-10-CM code J84.83, which is used for surfactant mutations of the lung. Include details on genetic testing, family history, and respiratory symptoms to justify the diagnosis.